Generic Drugs Market- Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028
Generic Drugs Market |
Medication classified as a
generic has the same active component as a branded drug. The therapeutic
effects of these medications are same, and they are prescribed with the same
dosage, quality, and usage patterns. However, compared to their branded
counterparts, generic medications' inactive components can vary. These
medications are primarily marketed after a branded drug's patent expires and
are much less expensive than the patented branded drugs. Generic medications
are produced using the same safety and manufacturing practises as branded
medications and are of an equal quality. After the period of patent exclusivity
expires, several manufacturers file an abbreviated new drug application (ANDA)
to the FDA.
The research and introduction of
novel medications and formulations, such as biosimilars, is a focus for generic
medicine manufacturers. IMS Health data show that over 80% of prescriptions
filled in the U.S. in 2013 were for generic medications. The Generic
Drugs Market is expected to rise significantly as a
result of the large number of patents that will expire soon. For instance, the
epidermal growth factor receptor inhibitor cetuximab (Erbitux) is recommended
for the treatment of head and neck cancer and metastatic colorectal cancer. In
Europe, Bristol-Myers Squibb and Eli Lily Company produce it in accordance with
the patent.
The drug's patent expires in
2018, which means a lot of market players will have the chance to produce its
generic equivalent. Additionally, the FDA's initiative to assist the
development of biosimilars is motivating firms to give it their full attention.
For instance, the U.S.'s Biologics Price Competition and Innovation Act grants
the first producer a 12-month patent exclusivity period with bigger profit
margins than the traditional generic manufacturers who release the
pharmaceuticals afterwards.
Types of Generic Drugs-
·
Monoclonal Antibodies
·
Cytokines
·
Vaccines
·
Insulin
·
Peptide Hormones
·
Immunoglobulin
·
Peptide Antibiotics
·
Blood Factors
The Generic Drugs Market is expanding due to
a number of additional causes, such as the epidemic rise in chronic illness
incidence. A lack of active pharmaceutical ingredients, which prevents generic
versions from being sold, as well as increased FDA pressure on producers to
improve the manufacturing quality of these drugs are, however, limiting market
expansion.
Comments
Post a Comment